Skip to main content
Clinical Trials/NCT04316676
NCT04316676
Completed
Not Applicable

MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)

Emory University1 site in 1 country20 target enrollmentJune 16, 2021

Overview

Phase
Not Applicable
Intervention
Regadenoson
Conditions
Coronary Artery Disease
Sponsor
Emory University
Enrollment
20
Locations
1
Primary Endpoint
Myocardial Blood Flow
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

Detailed Description

Participants will be patients who are scheduled to undergo PET Myocardial Perfusion Imaging, which is the traditional method for evaluating patients with suspected blockages or narrowing of the heart vessels (coronary artery disease) causing impaired blood to flow to the heart muscle (myocardium). The purpose of the study is to determine and compare the newest heart imaging equipment which allows the non-invasive evaluation of coronary anatomy, coronary flow and myocardial perfusion in patients with suspected or proven coronary artery disease (CAD) with the actual gold-standard for quantitative myocardial perfusion assessment. In order to achieve this aim, the study team will compare heart scan results from a computed tomography (CT) Myocardial Perfusion Imaging (CT-MPI) scan and CT-Fractional Flow Reserve (FFR) with the actual standard clinical care represented by a PET Myocardial Perfusion Imaging (PET-MPI) study.

Registry
clinicaltrials.gov
Start Date
June 16, 2021
End Date
September 24, 2024
Last Updated
3 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Carlo N. De Cecco

Associate Professor

Emory University

Eligibility Criteria

Inclusion Criteria

  • Referred for a clinically indicated CT-MPI for CAD assessment
  • Must provide written informed consent prior to any study-related procedures being performed
  • Must be willing to comply with all clinical study procedures

Exclusion Criteria

  • Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post-menopausal, with minimum one (1) year history without menses.
  • Currently taking or has taken within 48 hours the following excluded medications:
  • ActoPlus Met (Pioglitazone + metformin)
  • Avandamet (Rosiglitazone + metformin)
  • Fortamet (metformin)
  • Glucovance (Glyburide +metformin)
  • Glucophage (metformin)
  • Glucophage extended-release (XR) (metformin)
  • Glumetza (metformin)
  • Janumet (Sitagliptin + metformin)

Arms & Interventions

Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR

Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Intervention: Regadenoson

Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR

Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Intervention: PET-MPI Protocol

Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR

Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Intervention: CT-MPI

Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR

Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Intervention: Coronary CT angiography (CCTA) for CT-FFR calculation

Outcomes

Primary Outcomes

Myocardial Blood Flow

Time Frame: Day of PET-MPI Scan, and Day of CT-MPI and CT-FFR Scans (up to 90 days)

The absolute quantification of myocardial perfusion between CT-MPI and PET-MPI is compared. Myocardial perfusion is quantified using appropriate tracer kinetic models resulting myocardial blood flow mL/g/min.

Specificity of Myocardial Perfusion Abnormalities Diagnosis

Time Frame: Day 1 (day of scans)

The accuracy of detection of myocardial perfusion abnormalities is compared between PET-MPI, CT-MPI, CCTA, and CT-FFR approach. Diagnostic accuracy using CT-MPI, CCTA and CT-FFR is calculated as specificity (true negatives) with PET as the reference standard.

Coronary Flow Per CT-FFR

Time Frame: Day of CT-MPI and CCTA scans

Coronary flow is measured using the CT-FFR calculation with the CCTA scans. CT-FFR measures blood flow through coronary arteries and is used clinically to quantify the severity of CAD to determine further interventions. CT-FFR is the ratio between the blood flow (BF) in a diseased artery and a normal artery. Clinically, the CT-FFR calculation is only useful in patients with intermediate stenosis because stenosis below intermediate results in a value that is near zero and the calculation cannot be performed when stenosis is complete. The normal range for CT-FFR is greater than 0.80, values of 0.76 to 0.80 are borderline while values of 0.75 or less are associated with a high likelihood of reduced blood flow (ischemia).

Sensitivity of Coronary Stenosis Diagnosis

Time Frame: Day 1 (day of scans)

The accuracy of detection of coronary stenosis is compared between PET-MPI, CT-MPI, and CCTA with CT-FFR approach. Diagnostic accuracy is calculated as sensitivity (true positives) with CCTA as the reference standard.

Sensitivity of Myocardial Perfusion Abnormalities Diagnosis

Time Frame: Day 1 (day of scans)

The accuracy of detection of myocardial perfusion abnormalities is compared between PET-MPI, CT-MPI, CCTA, and CT-FFR approach. Diagnostic accuracy using CT-MPI, CCTA and CT-FFR is calculated as sensitivity (true positives) with PET as the reference standard.

Area Under the Curve (AUC) for Detection of Myocardial Perfusion Abnormalities

Time Frame: Day 1 (day of scans)

The accuracy of detection of myocardial perfusion abnormalities is compared between PET-MPI, CT-MPI, CCTA, and CT-FFR approach. Diagnostic accuracy using CT-MPI, CCTA and CT-FFR is calculated as overall AUC with PET as the reference standard. The AUC examines the overall accuracy of a diagnostic test. Higher AUC indicates greater accuracy in detecting myocardial perfusion abnormalities with 1.0 being 100% accurate. An AUC value of 0.5 indicates that the test is as accurate as random chance.

Specificity of Coronary Stenosis Detection

Time Frame: Day 1 (day of scans)

The accuracy of detection of coronary stenosis is compared between PET-MPI, CT-MPI, and CCTA with CT-FFR approach. Diagnostic accuracy is calculated as specificity (true negatives) with CCTA as the reference standard.

Area Under the Curve for Detection of Coronary Stenosis

Time Frame: Day 1 (day of scans)

The accuracy of detection of coronary stenosis is compared between PET-MPI, CT-MPI, and CCTA with CT-FFR approach. Diagnostic accuracy is calculated as overall AUC with CCTA as the reference standard. The AUC examines the overall accuracy of a diagnostic test. Higher AUC indicates greater accuracy in detecting coronary stenosis with 1.0 being 100% accurate. An AUC value of 0.5 indicates that the test is as accurate as random chance.

Study Sites (1)

Loading locations...

Similar Trials